Development of Nanostructures for Drug Delivery Applications

Biomedical Nanostructures

Volumn , Issue , 2007, Pages 139-206

  Dube, Nikhil ^a   Dutta, Joydeep ^a   Katti, Dhirendra S ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

Author keywords

Carbon nanotubes drug delivery applications; Drugs delivery to brain and central nervous system; Polymeric nanoparticles

Indexed keywords

EID: 84890587947     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470185834.ch7     Document Type: Chapter

References (438)

1. Mainardes RM and Silva LP. Drug delivery systems: past, present, and future. Curr Drug Targets 2004;5:449-455.
2. Ratner BD, Schoen FJ, Hoffman AS, Lemons JE. Biomaterials Science. St Louis: Elsevier Science & Technology Books; 2004. p 629-649.
3. Peppas LB. Polymers in controlled drug delivery. Med Plast Biomater Nov:1997; 34-40.
4. Vogelson CT. Advances in drug delivery systems. Mod Drug Discov 2001;4(52): 49-50.
5. Dreher MR, et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;36:335-344.
6. Mansouri S, et al. Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 2006;27:2060-2065.
7. Yang L. Development of tumor-targeted nanoparticles for in vivo tumor imaging and drug delivery. Nanomed Nanotechnol, Biol Med 2006;2(4):293-295.
8. Amiji MM. Nanotechnology for targeted drug and gene delivery. Nanomed Nanotechnol Biol Med 2006;2(4):299-300.
9. Gaillard PJ and Boer AG. A novel opportunity for targeted drug delivery to the brain. J Controll Release 2006;2(28):60-62.
10. Silva GA. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg Neurol 2005;63:301-306.
11. Lu Y and Chen SC. Micro and nano-fabrication of biodegradable polymers for drug delivery. Adv Drug Deliv Rev 2004;56:1621-1633.
12. Van D, McGuire T, Langer R. Small scale systems for in vivo drug delivery. Nat Biotechnol 2003;21(10):1184-1191.
13. Kim GJ and Nie S. Targeted cancer nanotherapy. Nanotoday August:2005;28-33.
14. Martin CR and Kohli P. The emerging field of nanotube biotechnology. Nat Rev Drug Discov 2003;2:29-37.
15. Xu P, et al. Highly stable core-surface-crosslinked nanoparticles as cisplatin carriers for cancer chemotherapy. Colloids Surf B Biointerfaces 2006;48:50-57.
16. Kneuer C, et al. Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. Int J Pharm 2000;196:257-261.
17. Luo D, Han E, Belcheva N, Saltzman WM. A self-assembled, modular DNA delivery system mediated by silica nanoparticles. J Control Release 2004;95: 333-341.
18. Sergiienko R, et al. Carbon encapsulated iron carbide nanoparticles synthesized in ethanol by an electric plasma discharge in an ultrasonic cavitation field. Mater Chem Phys 2006;98(1):34-38.
19. Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R. Synthesis of thiolderivatised gold nanoparticles in a two-phase system. J Chem Soc Chem Commun 1994;801-802.
20. Chen M, Feng Y, Wang L, Zhang L, Zhang J. Study of palladium nanoparticles prepared from water-in-oil microemulsion. Colloids Surf A 2006;281(1-3): 119-124.
21. Kayser O, Lemke A, Trejo NH. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 2005;6: 3-5.
22. Fishbein I, et al. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J Control Release 2000;65:221-229.
23. Nishioka Y and Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001;47:55-64.
24. Panagi Z, et al. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA--mPEG nanoparticles. Int J Pharm 2001;221:143-152.
25. Calvo P, et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 2002;15(8):1317-1326.
26. Zhang Y and Zhuo R. Synthesis and in vitro drug release behavior of amphiphilic triblock copolymer nanoparticles based on poly(ethylene glycol) and polycaprolactone. Biomaterials 2005;26(33):6736-6742.
27. Calvo P, et al. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J appl polym Sci 1997;63(1):125-132.
28. Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci 2001;12(3):251-259.
29. Zwiorek K, Kloeckner J, Wagner E, Coester C. Gelatin nanoparticles as a new and simple gene delivery system. J Pharm Pharm Sci 2004;7(4):22-28.
30. Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26(4):298-303.
31. Samaligey MS and Rohdewald P. Reconstituted collagen nanoparticles, a novel drug carrier delivery system. J Pharm Pharmacol 1983;35(8):537-539.
32. Hans ML and Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002;6:319-327.
33. Couvreur P and Vauthier C. Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives. J Control Release 1991;17:187-198.
34. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000;21:2475- 2490.
35. Coombes AGA. Design of nano and micro-particulate controlled release systems. Drug delivery company's report 2001/02. PharmaVentures Ltd;2001.
36. Alonso MJ, Gupta RK, Min C, Siber GR, Langer R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994;12(4): 299-306.
37. Zhanga Z and Feng S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006;27:262-270.
38. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/ glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Release 1993;25:89-98.
39. Guerrero DQ, Fessi H, Allemann E, Doelker E. Influence of stabilizing agents and preparative variables on the formation of poly(D,L-lactic acid) nanoparticles by an emulsification-diffusion technique. Int J Pharm 1996;143: 133-141.
40. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(DLlactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm 1999;187:143-152.
41. Kwon GS, et al. Block copolymer micelles as vehicles for hydrophobic drugs. Colloids Surf B Biointerfaces 1994;2:429-434.
42. Salvage JP, et al. Novel biocompatible phosphorylcholine-based self-assembled nanoparticles for drug delivery. J Control Release 2005;104:259-270.
43. Xu JP, Ji J, Chen WD, Shen JC. Novel biomimetic polymersomes as therapeutics for drug delivery. J Control Release 2005;107(3):502-512.
44. Fu YJ, Shyu SS, Su FH, Yu PC. Development of biodegradable co-poly(D,L-lactic/ glycolic acid) microspheres for the controlled release of 5-FU by the spray drying method. Colloids Surf B Biointerfaces 2002;25:269-279.
45. Leroux JC, Allemann E, Jaeghere FD, Doelker E, Gurny R. Biodegradable nanoparticles--from sustained release formulations to improved site specific drug delivery. J Control Release 1996;39:339-350.
46. Allemann E, Gurny R, Doelker E. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle size. Int J Pharm 1992;87:247-253.
47. Lukowski R, Miiller H, Müller BW, Dittgen M. Acrylic acid copolymer nanoparticles for drug delivery: characterization of the surface properties relevant for in vivo organ distribution. Int J Pharm 1992;84:23-31.
48. Behan N, Birkinshaw C, Clarke N. Poly(n-butylcyanoacrylate) nanoparticles: a mechanistic study of polymerisation and particle formation. Biomaterials 2001;22: 1335-1344.
49. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation methods for preparation of drug-loaded polymeric nanoparticles. Nanomed: Nanotechnol, Biol Med 2006;2:8-21.
50. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol 2005;78:1-10.
51. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20.
52. Chawla JS and Amiji MM. Biodegradable poly(o-caprolactone) nanoparticles for tumor targeted delivery of tamoxifen. Int J Pharm 2002;249:127-138.
53. Perez C, et al. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 2001;75:211-224.
54. Yoo HS, Lee KH, Oh JE, Park TG. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release 2000;68:419-431.
55. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3-19.
56. Vila A, Sanchez A, Tobo M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002;78:15-24.
57. Zhang Z and Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006;27:4025-4033.
58. Liu M, Dong J, Yang Y, Yang X, Xu H. Characterization and release of triptolide-loaded poly (D,L-lactic acid) nanoparticles. Eur Polym J 2005;41: 375-382.
59. Yamazaki N, et al. Endogenous lectins as targets for drug delivery. Adv Drug Deliv Rev 2000;43:225-244.
60. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54:631-651.
61. Peracchia MT, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 1999;60:121-128.
62. Couvreur P, Gref R, Andrieux K, Malvy C. Nanotechnologies for drug delivery application to cancer and autoimmune diseases. Prog Solid State Chem 2006; 34:231-235.
63. Kaul G and Amiji M. Biodistribution and targeting potential of polyethylene glycol- modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target 2004;12:585-591.
64. Kaul G and Amiji M. Tumor targeted gene delivery using polyethylene glycolmodified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 2005; 22(6):951-961.
65. Li YP, et al. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor carriers: pharmacokinetics and anti-tumor effects. Biol Pharm Bull 2001;24(6): 662-665.
66. Vittaz M, et al. Effect of PEO surface density on long circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 1996;17: 1575-1581.
67. Zeng Y and Pitt WG. Poly(ethylene oxide)-b-poly(N-isopropylacrylamide) nanoparticles with crosslinked cores as drug carriers. J Biomater Sci Polym Ed 2005;16(3):371-380.
68. Shenoy D, Little S, Langer R,Amiji M. Poly(ethylene oxide)-modified poly(b-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. Part I. In Vitro evaluations. Mol Pharmacol 2005;2(5): 357-366.
69. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81.
70. Roney C, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005;108:193-214.
71. Garcia EG, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier translocation: a way to deliver drugs to the brain. Int J Pharm 2005;298: 274-292.
72. Olivier JC. Drug transport to brain with targeted nanoparticles. J Am Soc Exp Neurother 2005;2:108-119.
73. Gao X, et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 2006;27:3482-3490.
74. Gao K and Jiang X. Influence of particle size on transport of methotrexate across blood-brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm 2006;310:213-219.
75. Michaelis K, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharm Exp Ther 2006;317(3): 1246-1253.
76. Mishra V, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 2006;14(1):45-53.
77. Costantino L, et al. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release 2005;108:84-96.
78. Lu W, et al. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 2005;107:428-448.
79. Krauzewicz N, et al. Virus-like gene transfer into cells mediated by polyomavirus pseudocapsids. Gene Ther 2000;7:2122-2131.
80. Leong KW, et al. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release 1998;53:183-193.
81. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001;52:145-150.
82. Mansouri S, et al. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm 2004;57:1-8.
83. Zhao X, Yu SB, Wu FN, Mao ZB, Yu CL. Transfection of primary chondrocytes using chitosan-pEGFP nanoparticles. J Control Release 2006;112: 223-228.
84. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005;60:247-266.
85. Santos AG, et al. Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFb-2 therapy. Pharm Res 2006;23(4):770-781.
86. Guliyeva U, Oner F, Ozsoy S, Haziroglu R. Chitosan microparticles containing plasmid DNA as potential oral gene delivery system. Eur J Pharm Biopharm 2006;62:17-25.
87. Silva GA. Introduction to nanotechnology and its applications to medicine. Surg Neurol 2004;61:216-220.
88. Yokoyama A, et al. Biological behaviour of hat stacked carbon nanofibers in subcutaneous tissue in rats. Nano Lett 2005;5(1):157-161.
89. Chen Z, et al. Structure of poly(ferrocenyldimethylsilane) in electrospun organometallic nanofibers. Macromolecules 2001;34(18):6164-6166.
90. Kameoka J, Verbridge SS, Lui H. Fabrication of suspended silica glass nanofibers using a scanned electrospinning source. Nano Lett 2004;4(11):2105-2108.
91. Zhang M, Bando Y, Wada K, Kurashima K. Synthesis of nanotubes and nanowires of silicon oxide. J Mater Sci Lett 1999;18(23):1911-1913.
92. Duncan R. The drawing era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-360.
93. Griffith LG. Polymeric biomaterials. Acta Mater 2000;48:263-277.
94. Zhang Y, Lim CT, Ramakrishna S, Huang ZM. Recent development of polymer nanofibers for biomedical and biotechnological applications. J Mater Sci-Mater Med 2005;16:933-946.
95. Ondarcuhu T and Joachim C. Drawing a single nanofiber over hundreds of microns. Eur Phys Lett 1998;42:215-220.
96. Thomson RC, Shung AK, Yaszemski MJ, Mikos AG. Polymer scaffold processing. In:Vacanti J, Lanza RP, Langer R, editors. Principles of Tissue Engineering. San Diego: Academic Press; 251-261.
97. Feng L, Li SJ, Song YL, Jiang L, Zhu DB. Template based synthesis of aligned polyacryonitrile nanofibers using a novel extrusion method. Synth Met 2003; 136:817-818.
98. Martin CR. Template synthesis of electronically conductive polymer nanostructures. Acc Chem Res November:1995;28:61-68.
99. Martin CR. Membrane-based synthesis of nanomaterials. Chem Mater 1996;8: 1739-1746.
100. Martin CR and Hulteen JC. A general template-based method for the preparation of nanomaterials. J Mater Chem 1997;7:1075-1087.
101. Guler MO, Claussen RC, Stupp SI. Encapsulation of pyrene within self-assembled peptide amphiphile nanofibers. J Mater Chem 2005;15:4507-4512.
102. Chen P. Self-assembly of ionic-complementary peptides: a physicochemical viewpoint. Colloids Surf A: Physicochem Eng Aspects 2005;261:3-24.
103. Hartgerink JD, Beniash E, Stupp SI. Peptide-amphiphile nanofibers: a versatile scaffold for the preparation of self-assembling materials. Proc Natl Acad Sci USA 2002;99(8):5133-5138.
104. Hartgerink JD, Paramonov SE, Jun HW. Self-assembly of peptide-amphiphile nanofibers: the roles of hydrogen bonding and amphiphilic packing. J Am Chem Soc 2006;128:7291-7298.
105. Niece KL, Hartgerink JD, Donners JM, Stupp SI. Self-assembly combining two bioactive peptide-amphiphile molecules into nanofibers by electrostatic attraction. J Am Chem Soc 2003;125:7146-7147.
106. Ma PX and Zhang R. Synthetic nano-scale fibrous extracellular matrix. J Biomed Mater Res 1999;46:60-72.
107. Frenot A and Chronakis IS. Polymer nanofibers assembled by electrospinning. Curr Opin Colloid Interface Sci 2003;8:64-75.
108. Reneker DH and Chun I. Nanometre diameter fibres of polymer, produced by electrospinning. Nanotechnology 1996;7:216-223.
109. Inai R, Kotaki M, Ramakrishna S. Structure and properties of electrospun PLLA single nanofibers. Nanotechnology 2005;16:208-213.
110. Li M, et al. Electrospun protein fibers as matrices for tissue engineering. Biomaterials 2005;26:5999-6008.
111. Smith LA and Ma PX. Nano-fibrous scaffolds for tissue engineering. Colloids Surf B Biointerfaces 2004;39:125-131.
112. Vasita R and Katti DS. Nanofibers and their applications in tissue engineering. Int J Nanomed 2006;1(1):15-30.
113. Shorey JD and Michelson D. On the mechanism of electrospraying. Nucl Instrum Methods 1970;82:295-296.
114. Xinhua Zong X, et al. Structure and process relationship of electrospun bioabsorbable nanofiber membranes. Polymer 2002;43:4403-4412.
115. Huang ZM, Zhang YZ, Kotaki M, Ramakrishna S. A review on polymer nanofibers by electrospinning and their applications in nanocomposites. Compos Sci Technol 2003;63:2223-2253.
116. Kosmider K and Scott J. Polymeric nanofibers exhibit an enhanced air filtration performance. Filtr Sep 2002;39(6):20-22.
117. Gibson HL, Truong Q, Walker JD, Jones WE. Chemical and biological protection and detection in fabrics for protective clothing. Mater Res Soc 2003;228(8): 123-128.
118. Pham QP, Sharma U, Mikos AG. Electrospinning of polymeric nanofibers for tissue engineering applications: a review. Tissue Eng 2006;12(5):1197-1211.
119. Salvay DM and Shea LD. Inductive tissue engineering with protein and DNAreleasing scaffolds. Mol Biosyst 2006;2:36-48.
120. Kenawy ER, et al. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release 2002;81:57-64.
121. Zeng J, et al. Biodegradable electrospun fibers for drug delivery. J Control Release 2003;92:227-231.
122. Kim K, et al. Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J Control Release 2004;98:47-56.
123. Cui W, et al. Investigation of drug release and matrix degradation of electrospun poly(DL-lactide) fibers with paracetanol inoculation. Biomacromolecules 2006;7: 1623-1629.
124. Katti DS, Robinson KW, Ko FK, Laurencin CT. Bioresorbable nanofiberbased systems for wound healing and drug delivery: optimization of fabrication parameters. J Biomed Mater Res B Appl Biomater 70(2):286-296.
125. Verreck G, et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J Control Release 2003;92:349-360.
126. Rosen HB, Chang J, Wnek GE, Linhardt RJ, Langer R. Bioerodible polyanhydrides for controlled drug delivery. Biomaterials 1983;4:131-133.
127. Taepaiboon P, Rungsardthong U, Supaphol P. Drug-loaded electrospun mats of poly(vinyl alcohol) fibres and their release characteristics of four model drugs. Nanotechnology 2006;17:2317-2329.
128. Huang ZM, et al. Encapsulating drugs in biodegradable ultrafine fibers through co-axial electrospinning. J Biomed Mater Res 2006;77:169-179.
129. Sun Z, et al. Compound core-shell nanofibers by coelectrospinning. Adv Mater 2003;15(22):1929-1932.
130. Jiang H, et al. Preparation and characterization of ibuprofen-loaded poly(lactideco-glycolide)/poly(ethylene glycol)-g-chitosan electrospun membranes. J Biomater Sci Polym Ed 2004;15(3):279-296.
131. Luu YK, Kim K, Hsiao BS, Chu B, Hadjiargyrou M. Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. J Control Release 2003;89:341-353.
132. Liang D, et al. In vitro non-viral gene delivery with nanofibrous scaffolds. Nucleic Acids Res 2005;33(19):1-8.
133. Zeng J, et al. Poly(vinyl alcohol) nanofibers by electrospinning as a protein delivery system and the retardation of enzyme release by additional polymer coatings. Biomacromolecules 2005;6:1484-1488.
134. Jiang H, et al. A facile technique to prepare biodegradable coaxial electrospun nanofibers for controlled release of bioactive agents. J Control Release 2005;108: 237-243.
135. Jiang H, Fang D, Hsiao BS, Chu B, Chen W. Optimization and characterization of dextran membranes prepared by electrospinning. Biomacromolecules 2004;5: 326-333.
136. Vasita R and Katti DS. Growth factor-delivery systems for tissue engineering: a materials perspective. Expert Rev Med Devices 2006;1:29-47.
137. Chew SY, Wen J, Yim EF, Leong KW. Sustained release of proteins from electrospun biodegradable fibers. Biomacromolecules 2005;6:2017-2024.
138. Beaty CE and Saltzman MW. Controlled growth factor delivery induces differential neurite outgrowth in three-dimensional cell cultures. J Control Release 1993;24:15-23.
139. Elbert SS and Hubbell JA. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. J Control Release 2000; 69:149-158.
140. Lee AC, et al. Controlled release of nerve growth factor enhances sciatic nerve regeneration. Exp Neurol 2003;184:295-303.
141. Haller MF and Saltzman MW. Nerve growth factor delivery systems. J Control Release 1998;53:1-6.
142. Luginbuehl V, Meinel L, Merkle HP, Gander B. Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm 2004;58:197-208.
143. Holland TA, Tabata Y, Mikos AG. Dual growth factor delivery from degradable oligo(poly(ethyleneglycol) fumarate) hydrogel scaffolds for cartilage tissue engineering. J Control Release 2005;101:111-125.
144. Simmons CA, Alsberg E, Hsiong S, Kim WJ, Mooney DJ. Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone 2004;35:562-569.
145. Wei G, Jin Q, Giannobile WV, Ma PX. Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. J Control Release 2006;112: 103-110.
146. Lee JY, et al. Enhanced bone formation by controlled growth factor delivery from chitosan-based biomaterials. J Control Release 2002;78:187-197.
147. Park YJ, et al. Controlled release of platelet-derived growth factor-BB from chondroitin sulfate-chitosan sponge for guided bone regeneration. J Control Release 2000;67:385-394.
148. Markkanen JE, Rissanen TT, Antti Kivel A, Herttuala SY. Growth factorinduced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy. Cardiovasc Res 2005;65:656-664.
149. Sun Q, et al. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm Res 2005;22(7): 1110-1116.
150. Frechet JMJ and Tomalia D. Dendrimers and Other Dendritic Polymers. New York: John Wiley & Sons, Inc.; 2001.
151. Newkome GR, Moorefield CN, Vogtle F. Dendrimers and Dendrons: Concepts, Syntheses, Applications. Wiley-VCH; 2002.
152. Tomalia DA. Starburst dendrimers--nanoscopic supermolecules according to dendritic rules and principles. Macromol Symp 1996;101:243-255.
153. Hawker CJ and Frechet JMJ. Preparation of polymers with controlled molecular architecture--a new convergent approach to dendritic macromolecules. J Am Chem Soc 1990;112:7638-7647.
154. Esfand R and Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001;6:427-436.
155. Gillies ER and Frechet JMJ. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005;10:35-43.
156. Bosman AW, Janssen HM, Meijer EW. About dendrimers: structure, physical properties and applications. Chem Rev 1999;99:1665-1688.
157. Liu M and Frechet JMJ. Designing dendrimers for drug delivery. Pharm Sci Technol Today 1999;2(10):393-401.
158. Duncan R. Polymer conjugates for tumour targeting and intra-cytoplasmic delivery. the EPR effect as a common gateway? Pharm Sci Technol Today 1999;2:441-449.
159. vailable at www.dekker.com/sdek/93432345-48443502/.
160. Svenson S and Tomalia DA. Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev 2005;57:2106-2129.
161. Dufs C, Uchegbu IF, Schtzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005;57:2177-2202.
162. Klajnert B and Bryszewska M. Dendrimers: properties and applications. Acta Biochim Pol 2001;48:199-208.
163. Beezer AE, et al. Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water-soluble PAMAM derivatives. Tetrahedron 2003;59: 3873-3880.
164. Patri AK, et al. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 2005;57:2203-2214.
165. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999;10(8):767-776.
166. Zhuo RX, Du B, Lu ZR. In vitro release of 5-fluorouracil with cyclic core dendritic polymer. J Control Release 1999;57:249-255.
167. Marie RG. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:23-29.
168. Denis MM. Comparative toxicity of nonsteroidal anti-inflammatory drugs. Am J Med 1999;107:37-41.
169. Kolhe P, et al. Preparation, cellular transport, and activity of polyamidoaminebased dendritic nanodevices with a high drug payload. Biomaterials 2006;27: 660-669.
170. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003;259:143-160.
171. Yiyun C and Tongwen X. Dendrimers as potential drug carriers, Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem 2005;40:1188-1192.
172. Na M, et al. Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur J Med Chem 2006;41:670-674.
173. Bielinska AU, et al. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 1996;24:2176-2182.
174. Kukowska-Latallo JF, et al. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. Hum Gene Ther 2000;11: 1385-1395.
175. Eichman JD, Bielinska AU, Latallo JK, Baker JR. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharm Sci Technol Today 2000;3(7):232-245.
176. Haensler J and Szoka FC. Polyamidoaminecascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993;4:372-379.
177. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005;57:2177-2202.
178. Dhanikula RS and Hildgen P. Synthesis and evaluation of novel dendrimers with a hydrophilic interior as nanocarriers for drug delivery. Bioconjug Chem 2006; 17:29-41.
179. Bhadra D, Bhadra S, Jain NK. PEGylated peptide based dendritic nanoparticulate systems for delivery of artemether. J Drug Deliv Sci Technol 2005;15:65-73.
180. Ostro MJ and Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1989;46:1576-1587.
181. Available at http://en.wikipedia.org/wiki/Liposome.
182. Kshirsagar NA. Drug delivery systems. Indian J Pharma 2000;32:54-61.
183. Bangham AD and Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964;8:660-668.
184. Lasic DD. Novel applications of liposomes. Tibtech 1998;16:307-321.
185. Diederichs JE and Müller RH. Liposomen in kosmetika und arzneimitteln. Pharm Ind 1994;56:267-275.
186. Heath TD. Liposome dependent drugs. In:Gregoriadis G, editor. Liposomes as Drug Carriers: Trends and Progress. New York: John Wiley & Sons, Inc.; 1988. p 709-718.
187. Allemann E, Gurny R, Doelker E. Drug loaded nanoparticles-preparation methods and drug targeting issues. Eur J Pharm Biopharm 1993;39:173-191.
188. Smith A and Hunneyball IM. Evaluation of polylactide as a biodegradable drug delivery system for parenteral administration. Int J Pharm 1986;30:215-230.
189. Siekmann B and Westesen K. Sub-micron sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett 1992;1:123-126.
190. Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 1994;30:83-96.
191. Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 1993; 93:189-199.
192. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur J Pharm Biopharm 1996;43(2):110-115.
193. Müller RH, et al. Solid lipid nanoparticles (SLN) as an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995;41(1):62-69.
194. Bunjes H, Westesen K, Koch MHJ. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 1996;129:159-173.
195. Gasco MR. Solid lipid nanospheres from warm microemulsions. Pharm Technol Eur 1997;9(11):52-58.
196. Heiati H, Phillips NC, Tawashi R. Evidence for phospholipids bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm Res 1996;13(9):1406-1410.
197. Vringer T and Ronde HG. Preparation and structure of a water-in-oil cream containing lipid nanoparticles. J Pharm Sci 1995;84(4):466-472.
198. Sjostrom B, Kaplun A, Talmon Y, Cabane B. Structure of nanoparticles prepared from oil-in-water emulsions. Pharm Res 1995;12(1):39-48.
199. Dingler A, Blum RP, Niehus H, Gohla S, Müller RH. Solid lipid nanoparticles (SLN/Lipopearls): a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul 1999;16(6): 751-767.
200. Demirel M, Yazan Y, Müller RH, Kilic F, Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid particles. J Microencapsul 2001; 18(3):359-371.
201. Wissing SA and Müller RH. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release 2002;81:225-233.
202. Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 1993;89:9-12.
203. Morel S, Gasco MR, Cavalli R. Incorporation in lipospheres of [D-Trp-6]LHRH. Int J Pharm 1994;105:1-3.
204. Cavalli R, Morel S, Gasco MR, Chetoni P, Saettone MF. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int J Pharm 1995;117:243-246.
205. Sznitowska M, Gajewska M, Janicki S, Radwanska A, Lukowski G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration to rabbits. Eur J Pharm Biopharm 2001;52:159-163.
206. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54:131-155.
207. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121-128.
208. Radtke M and Müller RH. Comparison of structural properties of solid lipid nanoparticles (SLN) versus other lipid particles. Proc Int Symp Control Release Bioact Mater 2000;27:309-310.
209. Olbrich C, Gebner A, Kayser O, Müller RH. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002;10(5):387-396.
210. Müller RK, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery--a review of the state of the art. Eur J Pharm Biopharm 2005;50:161-177.
211. Hoffman RM, Margolis LB, Bergelson LD. Binding and entrapment of high molecular weight DNA by lecithin liposomes. FEBS Lett 1978;33:365-368.
212. Ridder M, Wang Y, Hofschneider PH. Liposomes as gene carriers: efficient transformation of mouse L cells by thymidine kinase gene. Science 1982;215:166-168.
213. Liu F, Yang J, Huang L, Liu D. Effect of non-ionic surfactants on the formation of DNA/emulsion complex and the emulsion-mediated gene transfer. Pharm Res 1997;13:1642-1646.
214. Watwe RM and Bellare JR. Manufacture of liposomes: a review. Curr Sci 1995;68:715-724.
215. Cortesi R, Esposito E, Luca G, Nastruzzi C. Production of lipospheres as carriers for bioactive compounds. Biomaterials 2002;23:2283-2294.
216. Lim SJ and Kim CK. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm 2002;243:135-146.
217. Siekmann B, Bunjes H, Koch MHJ, Westesen K. Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride-water phases. Int J Pharm 2002;244:33-43.
218. Lippacher A, Müller RH, Mader K. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm 2001;214:9-12.
219. Lippacher A, Müller RH, Mader K. Semisolid SLN dispersions for topical application: influence of formulation and production parameters on microstructure. Eur J Pharm Biopharm 2002;53(2):155-160.
220. Jenning V, Lippacher A, Gohla SH. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J Microencapsul 2002;19(1):1-10.
221. Dingler A and Gohla S. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J Microencapsul 2002;19(1):11-16.
222. Cavalli R, Caputo O, Marengo E, Pattarino F, Gasco MR. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie 1998;53:392-396.
223. Eldem T, Speiser P, Hincal A. Optimization of spray-dried and congealed lipid micropellets and characterisation of their surface morphology by scanning electron microscopy. Pharm Res 1991;8:47-54.
224. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3V,5Vdioctanoyl-5-fluoro-2V-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002;54:285-290.
225. Hou DZ, Xie CS, Huang KJ, Zhu CH. The production and characteristics of solid lipid nanoparticles. Biomaterials 2003;24:1781-1785.
226. Cortesi R, Esposito E, Luca G, Nastruzzi C. Production of lipospheres as carriers for bioactive compounds. Biomaterials 2002;23:2283-2294.
227. Shahgaldian P, Silva ED, Coleman AW, Rather B, Zaworotko MJ. Para-acylcalix-arene based solid lipid nanoparticles (SLN): a detailed study of preparation and stability parameters. Int J Pharm 2003;253:23-38.
228. Dubes A, et al. Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur J Pharm Biopharm 2003;55:279-282.
229. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 1998;38:583-92.
230. Gray A and Morgan J. Liposomes in hematology. Blood Rev 1991;5:258-271.
231. Longuet P, et al. Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusion in rats. Antimicrob Agents Chemother 1991;35:1303-1308.
232. Davidson RN, et al. Liposomal amphotericin B in drug-resistant leishmaniasis. Lancet 1991;337:1061-1062.
233. Gregoriadis G, Gursel I, Gursel M, McCormack B. Liposomes as immunological adjuvants and vaccine carriers. J Control Release 1996;41:49-56.
234. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Biotechnology 1995;13:527-537.
235. Oussoren C and Storm G. Targeting to lymph nodes by subcutaneous administration of liposomes. Int J Pharm 1998;162:39-44.
236. Gregoriadis G, Saffie R, DaSouza JB. Liposome mediated DNA vaccination. FEBS Lett 1997;402:107-110.
237. Kim CK and Jeong EJ. Development of dried liposome as effective immuno-adjuvant for hepatitis B surface antigen. Int J Pharm 1995;115:193-199.
238. Zabner J. Cationic lipids used in gene transfer. Adv Drug Deliv Rev 1997;27: 17-28.
239. Smith J, Zhang YL, Niven R. Toward development of a non-viral gene therapeutic. Adv Drug Deliv Rev 1997;26:135-150.
240. Felgner PL, et al. Lipofection--a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7417.
241. Reimer DL, et al. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 2001;44:12877-12883.
242. Wong FM, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry 2000;35:5756-5763.
243. Ferguson MR, et al. Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity. Biochem Biophys Res Comm 2006;344(3): 792-797.
244. Wong J, et al. Liposome-mediated transient transfection reduces cholesteroldependent coxsackievirus infectivity. J Virol Methods 2006;133(2):211-218.
245. Iwasa A, et al. Cellular uptake and subsequent intracellular trafficking of R8-liposomes. Biochim Biophys Acta Biomembr 2006;1758(6):713-720.
246. Cavalli R, Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 2000;10:305-309.
247. Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporine A in solid lipid nanoparticles. Int J Pharm 2002;241:341-344.
248. Souto EB and Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005;22:501-510.
249. Yang SC, et al. Distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999;59: 299-307.
250. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-1272.
251. Yamago S, et al. In vivo biological behavior of a water-miscible fullerene: C-14 labeling, absorption, distribution, excretion and acute toxicity. Chem Biol 1995;2(6):385-389.
252. Bianco A, et al. Biomedical applications of functionalized carbon nanotubes. Chem Commun 2005;571-577.
253. Dai H. Carbon nanotubes: opportunities and challenges. Surf Sci 2002;500: 218-241.
254. Resasco DE, et al. A scalable process for production of single-walled carbon nanotubes by catalytic disproportionation of CO on a solid catalyst. J Nanopart Res 2002;4:131-136.
255. Qingwen L, Jin Y, Zhogfan L. ependence of the formation of carbon nanotubes on the chemical structures of hydrocarbons. AdvNanomater Nanodevices 2002; 59-71.
256. Journet C and Bernier P. Production of carbon nanotubes. Appl Phys A 1998;1-9.
257. Morishita K and Takarada T. Scanning electron microscope observation of the purification behavior of carbon nanotubes. J Mater Sci 1999;34(6):1169-1174.
258. Bethune DS, et al. Cobalt-catalysed growth of carbon nanotubes with singleatomic-layer walls. Nature 1993;363:605-607.
259. Ebbesen TW and Ajayan PM. Large-scale synthesis of carbon nanotubes. Nature 1992;358:220-222.
260. Chiang M, et al. Electron field emission properties of pulsed laser deposited carbon films containing carbon nanotubes. J Vac Sci Technol 2001;19(3):1034-1039.
261. Guillard T, et al. Scale up of a solar reactor for fullerene and nanotube synthesis. J Sol Energy Eng 2002;124:22-27.
262. Bilodeau JF, Alexakis T, Meuniery JL, Tzantrizosz PG. Model of the synthesis of fullerenes by the plasma torch dissociation of C2Cl4. J Phys D: Appl Phys 1997; 30:2403-2410.
263. Kroto HW, Heath JR, Brien SC, Curl RF, Smalley RE. C60: buckminsterfullerene. Nature 1985;318:162-165.
264. Kratschmer W, Lamb LD, Fostiropoulos K, Huffman DR. Solid C60: a new form of carbon. Nature 1990;347:354-357.
265. Chuanchen S, Haibin G, Dufei F. Extraction of C60 cluster ion beam. Rev Sci Instrum 1994;65:1405-1409.
266. Sinha N and Yeow JW. Carbon nanotubes for biomedical applications. IEEE Trans Nanobiosci 2005;4(2):180-195.
267. Dyke CA, Stewart MP, Tour JM. Separation of single-walled carbon nanotubes on silica gel: materials morphology and Raman excitation wavelength affect data interpretation. J Am Chem Soc 2005;127:4497-4509.
268. Georgakilas V, et al. Purification of HiPCO carbon nanotubes via organic functionalization. J Am Chem Soc 2002;124:14318-14319.
269. Zhao B, et al. Chromatographic purification and properties of soluble singlewalled carbon nanotubes. J Am Chem Soc 2001;123:11673-11677.
270. Niyogi S, et al. Chromatographic purification of soluble single-walled carbon nanotubes. J Am Chem Soc 2001;123:733-734.
271. Shvedova AA, Castranova V. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health 2003;66(20):1909-1926.
272. Riviere NA, Nemanich RJ, Inman AO, Wang YY, Riviere JE. Multi-walled carbon nanotube interactions with human epidermal keratinocytes. Toxicol Lett 2005;155(3):377-384.
273. Lam C, James JT, McCluskey R, Hunter R. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci 2004;77(1):126-134.
274. Warheit DB, et al. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci 2004;77(1):117-125.
275. Huczko A, Lange H, Bystrzejewski M, Baranowski. Pulmonary toxicity of 1-D nanocarbon materials. Fullerenes Nanotubes Carbon Nanostruct 2005;13(2): 141-145.
276. Müller J, et al. Respiratory toxicity of multi-wall carbon nanotubes. Toxicol App Pharmacol 2005;207(3):221-231.
277. Garibaldi S, Brunelli C, Bavastrello V, Ghigliotti G, Nicolini C. Carbon nanotube biocompatibility with cardiac muscle cells. Nanotechnology 2006;17:391-397.
278. Bianco A, et al. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 2005;9:674-679.
279. Star A, Steuerman DW, Heath JR, Stoddart JF. Starched carbon nanotubes. Angew Chem Int Ed 2002;41(14):2508-2512.
280. Zheng M, et al. DNA-assisted dispersion and separation of carbon nanotubes. Nat Mater 2003;2:338-342.
281. Chen RJ, Zhang Y, Wang D, Dai H. Noncovalent sidewall functionalization of single-walled carbon nanotubes for protein immobilization. J Am Chem Soc 2001;123:3838-3839.
282. Pantarotto D, et al. Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew Chem Int Ed 2004;43:5242-5246.
283. Islam MF, Rojas E, Bergey DM, Johnson AT, Yodh AG. High weight fraction surfactant solubilization of single-wall carbon nanotubes in water. Nano Lett 2003;3:269-273.
284. Liu J, et al. Fullerene pipes. Science 1998;280:1253-1256.
285. Georgakilas V, et al. Organic functionalization of carbon nanotubes. J Am Chem Soc 2002;124:760-761.
286. Georgakilas V, et al. Amino acid functionalization of water-soluble carbon nanotubes. Chem Commun 2002;24:3050-3051.
287. Bianco A, et al. Carbon nanotubes: on the road to deliver. Curr Drug Deliv Rev 2005;2:253-259.
288. Planeix JM, et al. Application of carbon nanotubes as supports in heterogeneous catalysis. J Am Chem Soc 1994;116(17):7935-7936.
289. Saito S. Carbon nanotubes for next-generation electronics devices. Science 1997;278:77-78.
290. Kim P and Lieber CM. Nanotube nanotweezers. Science 1999;286:2148-2150.
291. Collins PG, Zettl A, Bando H, Thess A, Smalley RE. Nanotube nanodevice. Science 1997;278:100-102.
292. Mitchell DT, et al. Smart nanotubes for bioseparations and biocatalysis. J Am Chem Soc 2002;124:11864-11865.
293. Wu W, et al. Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed 2005;44:6358-6362.
294. Pastorin G, et al. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun 2006;11:1182-1184.
295. Yinghuai Z, et al. Substituted carborane-appended water-soluble single-wall carbon nanotubes: new approach to boron neutron capture therapy drug delivery. J Am Chem Soc 2005;127:9875-9880.
296. Rojas-Chapana J, Troszczynska J, Firkowska I, Morsczeck C, Giersig M. Multiwalled carbon nanotubes for plasmid delivery into Escherichia coli cells. Lab Chip 2005;5:536-539.
297. Singh R, et al. Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based gene delivery vectors. J Am Chem Soc 2005;127:4388-4396.
298. Kam NS, Liu Z, Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 2005;127:12492-12493.
299. Kam NS and Dai H. Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J Am Chem Soc 2005;127:6021-6026.
300. Kam NS, Jessop TC, Wender PA, Dai H. Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells. J Am Chem Soc 2004;126:6850-6851.
301. Pantarotto D, et al. Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem Biol 2003;10: 961-966.
302. Rasenick MM, Watanabe M, Lazarevic MB, Hatta S, Hamm HE. Synthetic peptides as probes for g protein function. J Biol Chem 1994;269(34):21519- 21525.
303. Bianco A, et al. Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties. J Am Chem Soc 2005;127: 58-59.
304. Schergna S, et al. Enzymatic modification of fullerene derivatives. Tetrahedron Lett 1998;39(42):7791-7794.
305. Kurz AH, Halliwell CM, Davis JJ, Hill AO, Canters GW. A fullerene-modified protein. Chem Commun 1998;433-434.
306. vailable at http://www.csixty.com/development.html.
307. Dugan LL, et al. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 1997;94:9434-9439.
308. Foley S, et al. Cellular localisation of a water-soluble fullerene derivative. Biochem Biophys Res Commun 2002;294:116-119.
309. Friedman SH, et al. Inhibition of the HIV-1 protease by fullerene derivatives: model building studies and experimental verification. J Am Chem Soc 1993;115: 6506-6509.
310. Gonzalez AK, Wilson LJ, Wu W, Nancollas GH. Synthesis and in vitro characterization of a tissue-selective fullerene: vectoring C60(OH)16AMBP to mineralized bone. Bioorg Med Chem 2002;10:1991-1997.
311. Tsao N, et al. In vitro action of carboxyfullerene. J Antimicrob Chemother 2002;49:641-649.
312. Isobe H, et al. Nonviral gene delivery by tetraamino fullerene. Mol Pharmacol 2006;3(2):124-134.
313. Ashcroft JM, et al. Fullerene (C60) immunoconjugates: interaction of watersoluble C60 derivatives with the murine anti-gp240 melanoma antibody. Chem Commun 2006;3004-3006.
314. Rancan F, et al. Fullerene-pyropheophorbide a complexes as sensitizer for photodynamic therapy: uptake and photo-induced cytotoxicity on Jurkat cells. J Photochem Photobiol B: Biol 2005;80:1-7.
315. Zakharian TY, et al. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J Am Chem Soc 2005;127:12508-12509.
316. Cagle DW, Kennel SJ, Mirzadeh S, Michael Alford J, Wilson LJ. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc Natl Acad Sci 1999;96:5182-5187.
317. Bolskar RD, et al. First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60[C(COOH)2]10 as a MRI contrast agent. J Am Chem Soc 2003;125:5471-5478.
318. Kato H, et al. Lanthanoid endohedral metallofullerenols for MRI contrast agents. J Am Chem Soc 2003;125:4391-4397.
319. Lee I and Akiyoshi K. Single molecular mechanics of a cholesterol-bearing pullulan nanogel at the hydrophobic interfaces. Biomaterials 2004;25:2911-2918.
320. Candau F, Daoud M, Williams CE. Soft Matter Physics. New York: Springer; 1995.
321. Antonietti M, Bremser W, Schmid M. Clusters and colloids: from theory to applications. Macromolecules 1990;23:3796-3805.
322. Antonietti M. Microgels-colloidal models for the cross-linked state. Macromol Symp 1995;93:213-225.
323. Antonietti M, Pakula T, Bremser W. Rheology of small spherical polystyrene microgels: a direct proof for a new transport mechanism in bulk polymers besides reptation. Macromolecules 1995;28:4227-4233.
324. Kuckling D, Vo CD, Wohlrab SE. Preparation of nanogels with temperatureresponsive core and pH responsive arms by photocrosslinking. Langmuir 2002; 18:4263-4269.
325. Zhou J, Li Z, Liu G. Diblock copolymer nanospheres with porous cores. Macromolecules 2002;35:3690-3696.
326. Daubresse C, Grandfils C, Jerome R, Teyssie P. Enzyme immobilization in nanoparticles produced by inverse microemulsion polymerization. J Colloid Interface Sci 1994;168:222-229.
327. Daubresse C, et al. Synthesis and inverse emulsion polymerization of aminated acrylamidodextran. J Pharm Pharmacol 1993;45:1018-1023.
328. Gupta AK, Madan S, Majumdar DK, Maitra A. Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies. Int J Pharm 2000;209:1-14.
329. Gaur U, et al. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000;202:1-10.
330. Madan T, et al. Biodegradable nanoparticles as a sustained release system for the antigens/allergens of Aspergillus fumigatus: preparation and characterisation. Int J Pharm 1997;159:135-147.
331. Harth E, et al. A facile approach to architecturally defined nanoparticles via intramolecular chain collapse. J Am Chem Soc 124:8653-8660.
332. Mecerreyes D, et al. A novel approach to functionalized nanoparticles: selfcrosslinking of macromolecules in ultradilute solution. Adv Mater 2001;13: 204-207.
333. Gregor HP, Samuelson E, Dalven PI, Gregor CD. Homopolymers and copolymers of acrylamide N-substituted acrylamide or N-substituted methacrylamide solid state cross-linked with polyamines or polyols.US patent 5,280,078. 1994.
334. Gan D and Lyon LA. Tunable swelling kinetics in core-shell hydrogel nanoparticles. J Am Chem Soc 2001;123:7511-7517.
335. Jones CD and Lyon LA. Synthesis and characterization of multiresponsive core-shell microgels. Macromolecules 2000;33:8301-8306.
336. Kadlubowski S, Grobelny J, Olejniczak W, Cichomski M, Ulanski P. Pulses of fast electrons as a tool to synthesize poly(acrylic acid) nanogels: intramolecularcross-linkingof linear polymer chains in additive-free aqueous solution. Macromolecules 2003;36:2484-2492.
337. Ulanski P, Kadlubowski S, Rosiak JM. Synthesis of poly(acrylic acid) nanogels by preparative pulse radiolysis. Radiat Phys Chem 2002;63:533-537.
338. Corrigan VG and Zawacky SR. Cationic microgels and their use in electrodeposition.US patent 5,096,556. 1992.
339. Gajria C and Ozari Y. Water-swellable crosslinked polymeric microgel particles and aqueous dispersions of organic film-forming resins containing the same. US patent 4,560,714. 1985.
340. Quadrat O and Snuparek J. Structure and flow properties of latexes containing carboxylic groups. Prog Org Coat 1990;18:207-228.
341. Biffis A. Functionalised microgels: novel stabilizers for catalytically active metal colloids. J Mol Catal A: Chem 2001;165:303-307.
342. Morris GE, Vincent B, Snowden MJ. The interaction of nanothermosensitive, anionic microgels with metal ion solution species. Prog Colloid Polym Sci 1997; 105:16-22.
343. Sawai T, Ikariyama Y, Aizawa M. Electrically modulated/flocculation of ultra fine microgels. In:Proceedings of the International Conference on Intelligent Materials; 1993; p 279.
344. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000;50:27-46.
345. Kiserab PF, Wilson G, Needham D. Lipid-coated microgels for the triggered release of doxorubicin. J Control Release 2000;68:9-22.
346. Guzman LA, et al. Local intraluminal infusion of biodegradable polymeric nanoparticles: a novel approach for prolonged drug delivery after balloon angioplasty. Circulation 1996;94:1441-1448.
347. Morimoto M, Endo T, Ohtomi M, Iwasaki Y, Akiyoshi K. Hybrid nanogels with physical and chemical cross-linking structures as nanocarriers. Macromol Biosci 2005;5:710-716.
348. Moshfeghi AA and Peyman GA. Micro- and nanoparticulates. Adv Drug Deliv Rev 2005;57:2047-2052.
349. Winet H, Hollinger JO, Stevanovic M. Incorporation of polylactide-polyglycolide in a cortical defect: neoangiogenesis and blood supply in a bone chamber. J Orthop Res 1995;13:679-689.
350. Kuckling D, Vo CD, Wohlrab SE. Preparation of nanogels with temperatureresponsive core and pH-responsive arms by photo-cross-linking. Langmuir 2002; 18:4263-4269.
351. Shin Y, et al. Hybrid nanogels for sustainable positive thermosensitive drug release. J Control Release 2001;73:1-6.
352. Jeong B, Kim S, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev 2002;54:37-51.
353. Sershen S and West J. Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev 2003;55:439-446.
354. Lowman AM, Takayama K, Nagai T, Peppas NA. Elucidation of the mechanism of incorporation of insulin in controlled release systems based on complexation polymers. J Control Release 2002;81:25-32.
355. Lowman AM, Morishita M, Kajita M, Nagai T, Peppas NA. Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci 2003;88(9):933-937.
356. Podual K, Doyle FJ, Peppas NA. Dynamic behavior of glucose oxidase-containing microparticles of poly(ethylene glycol)-grafted cationic hydrogels in an environment of changing pH. Biomaterials 2000;21:1439-1450.
357. Podual K, Doyle FJ, Peppas NA. Preparation and dynamic response of cationic copolymer hydrogels containing glucose oxidase. Polymer 2000;41:3975-3983.
358. Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 2004;15:50-60.
359. Soni S, Babbar AK, Sharma AK, Maitra M. Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels. J Drug Target 2006;14(2):87-95.
360. McAllister K, et al. Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents. J Am Chem Soc 2002;124:15198-15207.
361. Bronich TK, Vinogradov SV, Kabanov AV. Interaction of nanosized copolymer networks with oppositely charged amphiphilic molecules. Nano Lett 2001;1: 535-540.
362. Zuber G, Dauty E, Nothisen M, Belguise P, Behr JP. Towards synthetic viruses. Adv Drug Deliv Rev 2001;52:245-253.
363. Knowles MR, et al. Adenoviral-vector-mediated gene transfer for cystic fibrosis. N Eng J Med 1995;333(13):823-831.
364. Lai CM, et al. Controlled production of active cathepsin D in retinal pigment epithelial cells following adenovirus-mediated gene delivery. Mol Ther 2000;2(5):476-484.
365. Lazennec G and Katzenellenbogen BS. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormonedependent features to estrogen receptor-negative breast carcinoma cells. Mol Cell Endocrinol 1999;149:93-105.
366. Noad R and Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11(9):438-444.
367. Garcea RL and Gasman L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol 2004;15:513-517.
368. Grinshtein N. Recombinant adenovirus vaccines can successfully elicit CD8+ T cell immunity under conditions of extreme leukopenia. Mol Ther 2006;13(2): 270-279.
369. Graham FL and Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995;3:207-220.
370. Robbins PD and Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998;80(1):35-47.
371. Kamiya H, Tsuchiya H, Yamazaki J, Harashima H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors. Adv Drug Deliv Rev 2001;52:153-164.
372. Verma IM and Somia N. Gene therapy: promises, problems and prospects. Nature 1997;398(18):239-242.
373. Hruby DE. Vaccinia virus vectors: new strategies for producing recombinant vaccines. Clin Microbiol Rev 1990;3(2):153-170.
374. Sandler VM, et al. Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. J Neurosci Methods 2002;121:211-219.
375. Donofrio G, Martignani E, Cavirani S, Flammini CF. Exploiting persistent infection for selection of bovine herpesvirus 4 recombinants. J Virol Methods 2005;125:6-13.
376. Ketola A, Schlesinger S, Wahlfors J. Properties of Sindbis virus vectors produced with a chimeric split helper system. Int J Mol Med 2005;15(6): 999-1003.
377. Chou AK, et al. Intrathecal gene delivery of glial cell line-derived neurotrophic factor ameliorated paraplegia in rats after spinal ischemia. Mol Brain Res 2005;133:198-207.
378. Morrison DF and Murtaugh MP. Adenovirus-mediated expression of interleukin-1 receptor antagonist in swine cells in vitro and in vivo. Vet Immunol Immunopathol 2001;78:71-81.
379. Wang C, Chao C, Chao L, Chao J. Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. Immunopharmacology 1997;36:221-227.
380. Mason BB, et al. Adenovirus vaccine vectors expressing hepatitis B surface antigen: importance of regulatory elements in the adenovirus major late intron. Virology 1990;177:452-461.
381. Lubeck MD, et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci USA 1989;86:6763-6767.
382. Xiang ZQ, Yiping Y, Wilson JM, Ertl HJ. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996;219:220-227.
383. Wesley RD, Tang M, Lager KM. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 2004;22:3427-3434.
384. Imler JL. Adenovirus vectors as recombinant viral vaccines. Vaccine 1995;13(13): 1143-1151.
385. McTaggart S and Rubeai ML. Retroviral vectors for human gene delivery. Biotechnol Adv 2002;20:1-31.
386. Nagano M, Shinohara T, Avarbock MR, Brinster RL. Retrovirus-mediated gene delivery into male germ line stem cells. FEBS Lett 2000;475:7-10.
387. Du L, et al. Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther 2004;10(3):604-608.
388. Rivera VM, et al. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci USA 1999;96:8657-8662.
389. Ye X, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999;283:88-91.
390. Auricchio A, et al. Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. Gene Ther 2002;9:963-971.
391. Auricchio A, et al. Pharmacological regulation of protein expression from adenoassociated viral vectors in the eye. Mol Ther 2002;6(2):238-242.
392. During MJ. Adeno-associated virus as a gene delivery system. Adv Drug Deliv Rev 1997;27:83-94.
393. Desrosiers RC, et al. Synthesis of bovine growth hormone in primates by using a herpesvirus vector. Mol Cell Biol 1985;5:2796-2803.
394. Simmer B, et al. Persistence of selectable herpesvirus saimiri in various human haematopoietic and epithelial cell lines. J Gen Virol 1991;72:1953-1958.
395. Stevenson AJ, et al. Assessment of herpesvirus saimiri as a potential human gene therapy vector. J Med Virol 1999;57:269-277.
396. Donofrio G, Cavirani S, Simone T, Van Santen VL. Potential of bovine herpesvirus 4 as a gene delivery vector. J Virol Methods 2002;101:49-61.
397. Krisky DM, et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther 1998;5(12):1593-1603.
398. Lilley CE, et al. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J Virol 2001;4343-4356.
399. Costantini C, et al. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 1999;10(15):2481-2494.
400. Emborg ME, Deglon N, Leventhal L, Aebischer P, Kordower JH. Viral vectormediated gene therapy for Parkinson's disease. Clin Neurosci Res 2001;1: 496-506.
401. Lesch KP. Gene transfer to the brain: emerging therapeutic strategy in psychiatry. Soc Biol Psychiatry 1999;45:247-253.
402. Feldman LJ and Steg G. Optimal techniques for arterial gene transfer. Cardiovasc Res 1997;35:391-404.
403. Parry S, Koi H, Strauss JF. Transplacental drug delivery: gene and virus delivery to the trophoblast. Adv Drug Deliv Rev 1999;38:69-80.
404. Ou WC, et al. The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells. J Gen Virol 1999;80:39-46.
405. Touze A and Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 1998;26(5):1317-1323.
406. Kirnbauer R, Booy G, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-12184.
407. Rose RC, Bonnez R, Reichman C, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993;67:1936-1944.
408. Volpers CP, Schirmacher RE, Sapp M. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 1994;200:504-512.
409. Zhou J, Stenzel DJ, Sun XY, Frazer IH. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol 1993;74:763-768.
410. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993;67:315-322.
411. Breitburd F, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69(6):3959-3963.
412. Christenson ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70(2):960-965.
413. Suzich JA, et al. Systemic immunization with papillomavirus L1 protein prevents the development of viral mucosal papillomas completely. Proc Natl Acad Sci USA 1995;92:11553-11557.
414. Balmelli C, Demotz S, Orbea HA, Grandi PD, Haefliger DN. Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus Type 16 virus-like particles. J Virol 2002;76(24):12596-12602.
415. Silva DD, et al. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol 2001;13(5):633-641.
416. Nicholls PK and Stanley MA. The immunology of animal papillomaviruses. Vet Immunol Immunopathol 2000;73:101-127.
417. Forstova J, et al. Cooperation of structural proteins during late events in the life cycle of polyomavirus. J Virol 1993;67(3):1405-1413.
418. Henke S, Rohmann A, Bertling WM, Dingermann T, Zimmer A. Enhanced in vitro oligonucleotide and plasmid DNA transport by VP1 virus-like particles. Pharm Res 2000;17(9):1062-1070.
419. Chang D, et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J Gen Virol 1997;78:1435-1439.
420. Pawlita M, Müller M, Oppenlnder M, Zentgraf H, Herrmann M. DNA encapsidation by viruslike particles assembled in insect cells from the major capsid protein VP1 of B-lymphotropic papovavirus. J Virol 1996;70(11):7517- 7526.
421. Sandalon Z and Oppenheim A. Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology 1997;237: 414-421.
422. Rodgers RD, Chang D, Cai X, Consigli RA. Purification of recombinant budgerigar fledgling disease virus VP1 capsid protein and its ability for in vitro capsid assembly. J Virol 1994;68(5):3386-3390.
423. Schmidt U, Gunther C, Rudolph R, Bohm G. Protein and peptide delivery via engineered polyomavirus-like particles. FASEB J 2001;15:1646-1648.
424. Goldmann C, et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol 1999;73(5): 4465-4469.
425. Abbing A, et al. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 2004;279(26):27410-27421.
426. Merisko E. Liversidge nanocrystals: resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. In: Marty JJ, editor. Particles. Orlando: Marcel Dekker; 2002.
427. Lee J. Drug nano- and microparticles processed into solid dosage forms: physical properties. J Pharm Sci 2003;92:2057-2068.
428. Lee J. Intrinsic adhesion force of lubricants to steel surface. J Pharm Sci 2004;93:2310-2318.
429. Liu R. Water-Insoluble Drug Formation. Buffalo, IL: Inter-Pharm Press; 2000. p 455.
430. Fromming KS and Fromming J. Cyclodextrines in Pharmacy. Dordrecht: Kluwer Academic Publishers; 1993.
431. Müller RH. Dispersions for the formulation of slightly or poorly soluble drugs. PCT/EP01/08726, PharmasSol GmbH Berlin; 2001.
432. Choi JY, Yoo JY, Kwak HS, Nam BU, Lee J. Role of polymeric stabilizers for drug nanocrystal dispersions. Curr Appl Phys 2005;5:472-474.
433. Sucker H and Gassmann P. Improvements in pharmaceutical compositions.GB patent 2,269,536. Sandozy Ltd;1994.
434. Buchmann S, Fischli W, Thiel FP, Alex R. Aqueous microsuspension, an alternative intravenous formulation for animal studies. In: 42nd Annual Congress of the International Association for Pharmaceutical Technology; Mainz;1996. p 124.
435. Müller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. US patent 5,858,410. 1999.
436. Müller RH, Mader K, Krause K. Verfahren zur schonenden Herstellung von hochfeinen Micro-/Nanopartikeln. PCT application PCT/EP00/06535. Germany; 2000.
437. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785-796.
438. Müller RH and Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int J Pharm 1998;60:229-237.